[go: up one dir, main page]

WO2009151456A1 - Composés de thiazole, compositions et procédés utilisant ces derniers - Google Patents

Composés de thiazole, compositions et procédés utilisant ces derniers Download PDF

Info

Publication number
WO2009151456A1
WO2009151456A1 PCT/US2008/066867 US2008066867W WO2009151456A1 WO 2009151456 A1 WO2009151456 A1 WO 2009151456A1 US 2008066867 W US2008066867 W US 2008066867W WO 2009151456 A1 WO2009151456 A1 WO 2009151456A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
composition
cancer
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/066867
Other languages
English (en)
Inventor
Bassam Damaj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Quant Inc
Original Assignee
Bio Quant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Quant Inc filed Critical Bio Quant Inc
Priority to EP08770971A priority Critical patent/EP2307010A1/fr
Priority to JP2011513469A priority patent/JP2011522887A/ja
Priority to CA2727595A priority patent/CA2727595A1/fr
Priority to CN2008801303663A priority patent/CN102112129A/zh
Priority to PCT/US2008/066867 priority patent/WO2009151456A1/fr
Publication of WO2009151456A1 publication Critical patent/WO2009151456A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • Cancer is a significant health problem throughout the world.
  • the most frequently diagnosed cancers include colon cancer, lung cancer, breast cancer, prostate cancer, liver cancer, stomach cancer, esophagus cancer, and kidney cancer. These cancers represent a majority of cancers diagnosed in the U.S. population and account for over 90% of the cancer-related death in the U.S.
  • kidney cancer For example, in adults, the most common type of kidney cancer is renal cell carcinoma, which begins in the cells that line the small tubes within the kidneys. Children are more likely to develop a kind of kidney cancer called Wilms' tumor.
  • the American Cancer Society estimates that almost 51,000 people in the United States are diagnosed with kidney cancer each year. According to the Mayo Clinic, the incidence of kidney cancer is increasing.
  • cytotoxic agents remain the mainstay of cancer treatment, and because the oral and gastrointestinal mucosa is often significantly damaged by cancer therapy, management of these agents and associated effects is an important challenge for oncologists, and there remains a need for agents that minimize side effects and/or can be administered with cytotoxic agents to minimize such effects.
  • the present invention provides compounds and compositions as disclosed herein. Further, methods of treating cancers, for example kidney cancer, by administering to a patient in need thereof a disclosed compound or composition are disclosed herein.
  • rovided herein is a composition suitable for administering to a patient, comprising:
  • R 1 is selected from the group consisting of: -alkylene-R5-R6-R 2 , -R 6 - C(O)-phenyl, -R ⁇ -phenyl, alkyl, alkenyl or alkynyl, wherein the phenyl, independently for each occurrence, is optionally substituted by one or two moieties selected from the group consisting of halo, alkyl, CN, or NO 2 ;
  • R 2 is a heteroaryl optionally substituted by at one, two or three positions by halo, CN or alkyl;
  • R 3 independently for each occurrence, is selected from the group consisting of H, halo, CN, and NO 2 ;
  • R 4 is selected from the group consisting of thio, sulfonyl, or sulfinyl;
  • R 5 is selected from the group consisting of thio, sulfonyl, or sulfinyl;
  • Re is alkylene or a bond; or pharmaceutically acceptable salts thereof; and b) a pharmaceutically acceptable excipient.
  • R 2 for example, may be a bicyclic or monocyclic heteroaryl.
  • R 2 may be selected from the group consisting of benzothiazole, benzooxazole, isoquinoline, and pyridine.
  • at least one R 3 is NO 2 and/or R 1 is alkyl or -alkylene-phenyl.
  • R 1 may be methylbenzene, optionally substituted at one position by halo or R 1 may be ethyl or methyl.
  • least one R 3 is H.
  • R 6 is a bond.
  • R 5 maybe, for example, S.
  • R 4 is sulfonyl.
  • the disclosed compositions may also include achemotherapeutic agent, for example a chemotherapeutic agent selected from the group consisting of cisplatin, 5-fluorouracil, and vinblastine.
  • An article of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material is also provided, wherein the packaging material comprises a label which indicates that the pharmaceutical composition can be used for treatment of cancer and/or gastrointestinal symptoms, alone or in conjunction with administration of chemotherapeutics, and wherein the pharmaceutical composition comprises at least one compound of formula I, as shown and described above.
  • Also provided herein is a method of treating cancer, e.g. kidney cancer, ovarian cancer, leukemia, lung cancer, bladder cancer, breast cancer, liver cancer, or thyroid cancer, in a patient in need thereof, comprising administering an effective amount of at least one compound represented by formula II:
  • X is selected from the group of O, NR' and S; wherein R' is H or alkyl;
  • R 1 is selected from the group consisting of: -alkylene-R5-R6-R 12 , -R O -C(O)-R 12 , - R 6 -R 12 , alkyl, alkenyl, or alkynyl;
  • R 4 is selected from the group consisting of thio, sulfonyl, or sulfinyl;
  • R 5 is selected from the group consisting of thio, sulfonyl, or sulfinyl; - A -
  • Re is alkylene or a bond
  • R 12 is an aryl or heteroaryl optionally substituted by at one, two or three positions by halo, hydroxyl, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, amido, carbamoyl, sulphamoyl, ureido, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, or alkoxycarbonyl, and
  • R 3 independently for each occurrence, is selected from the group consisting of H, halo, cyano, hydroxyl, carboxy, alkyl, alkoxy, and nitro;
  • R 12 of formula II may be for example a heteroaryl optionally substituted by at one, two or three positions by halo, CN or alkyl, e.g. a bicyclic or monocyclic heteroaryl.
  • R 12 may be, in certain embodiments, selected from the group consisting of benzothiazole, benzooxazole, isoquinoline, and pyridine.
  • At least one R 3 is NO 2 and/or R 1 is alkyl or -alkylene-phenyl.
  • R 1 in another embodiment, may be is methylbenzene, optionally substituted at one position by halo, or may be ethyl or methyl.
  • R 3 is H.
  • R 6 is a bond.
  • R 5 may be S in certain embodiments and/or R 4 may be sulfonyl.
  • Such methods may further comprise administering another chemotherapeutic agent, such as cisplatin, 5-fluorouracil, or vinblastine.
  • a chemotherapeutic agent and a compound of formula II may be administered together in the same dosage form, or administered together in the separate dosage forms, either simulataneously or at a different time.
  • a method of improving therapeutic efficacy of a chemotherapeutic agent comprising administering to a patient in need thereof a compound represented by formula II, as shown above.
  • a method of inhibiting tumor growth comprising administering to a patient in need thereof a compound represented by formula II.
  • the present disclosure is directed in part towards compounds and compositions that inhibit tumor growth, e.g. growth of tumor cells such as kidney tumor ceils, and methods of making and using the same,
  • therapeutic agent refers to any chemical moiety that is a biologically, physiologically, or pharmacologically active substance that acts locally or systemically in a subject.
  • therapeutic agents also referred to as “drugs”
  • drug are described in well-known literature references such as the Merck Index, the Physicians Desk Reference, and The Pharmacological Basis of Therapeutics, and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances which affect the structure or function of the body; or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment.
  • the term "therapeutic effect” is art-recognized and refers to a local or systemic effect in animals, particularly mammals, and more particularly humans caused by a pharmacologically active substance.
  • the term thus means any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or in the enhancement of desirable physical or mental development and/or conditions in an animal or human.
  • the phrase "therapeutically-effective amount” means that amount of such a substance that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment.
  • the therapeutically effective amount of such substance will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • certain compositions of the present invention may be administered in a sufficient amount to produce a at a reasonable benefit/risk ratio applicable to such treatment.
  • modulation is art-recognized and refers to up regulation (i.e., activation or stimulation), down regulation (i.e., inhibition or suppression) of a response, or the two in combination or apart.
  • a "patient,” “subject” or “host” to be treated by the subject method may mean either a human or non-human animal.
  • alkyl is art-recognized, and includes saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
  • a straight chain or branched chain alkyl has about 30 or fewer carbon atoms in its backbone (e.g., C 1 -C 3 O for straight chain, C3-C30 for branched chain), and alternatively, about 20 or fewer, e.g. from 1 to 6 carbons.
  • cycloalkyls have from about 3 to about 10 carbon atoms in their ring structure, and alternatively about 5, 6 or 7 carbons in the ring structure.
  • alkyl is also defined to include halosubstituted alkyls.
  • alkyl (or “lower alkyl”) includes “substituted alkyls”, which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • Such substituents may include, for example, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety.
  • a carbonyl such as a carboxyl, an alkoxy
  • the moieties substituted on the hydrocarbon chain may themselves be substituted, if appropriate.
  • the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CN and the like. Exemplary substituted alkyls are described below. Cycloalkyls may be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl- substituted alkyls, -CN, and the like.
  • alkyl is art-recognized and refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
  • alkenyl and alkynyl are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
  • alkylene refers to an organic radical formed from an unsaturated aliphatic hydrocarbon; “alkenylene” denotes an acyclic carbon chain which includes a carbon-to-carbon double bond, both of which can be substituted as for alkyls, as discussed above.
  • lower alkyl refers to an alkyl group, as defined above, but having from one to about ten carbons, alternatively from one to about six carbon atoms (i.e. C 1-6 ) in its backbone structure.
  • lower alkenyl and “lower alkynyl” have similar chain lengths.
  • heteroatom is art- recognized and refers to an atom of any element other than carbon or hydrogen. Illustrative heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium.
  • aryl is art-recognized and refers to 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
  • aryl groups having heteroatoms in the ring structure may also be referred to as "heteroaryl” or “heteroaromatics.”
  • the aromatic ring may be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, -CF3, -CN, or the like.
  • aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
  • ortho, meta and para are art-recognized and refer to 1,2-, 1,3- and 1,4- disubstituted benzenes, respectively. For example, the names 1,2-dimethylbenzene and ortho- dimethylbenzene are synonymous.
  • heterocyclyl or “heterocyclic group” are art-recognized and refer to 3- to about 10-membered ring structures, alternatively 3- to about 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles may also be polycycles.
  • Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxanthene, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, o
  • the heterocyclic ring may be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF3, -CN, or the like.
  • substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl,
  • polycyclyl or “polycyclic group” are art-recognized and refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings.
  • Each of the rings of the polycycle may be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF3, -CN, or the like.
  • substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl
  • carrier is art-recognized and refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
  • nitro is art-recognized and refers to -NO2; the term “halogen” is art- recognized and refers to -F, -Cl, -Br or -I; the term “sulfhydryl” is art-recognized and refers to - SH; the term “hydroxyl” means -OH; and the term “sulfonyl” is art-recognized and refers to - SO2 " .
  • amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that may be represented by the general formulas:
  • R50, R51 and R52 each independently represent a hydrogen, an alkyl, an alkenyl, - (CH2)m-R61, or R50 and R51, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure;
  • R61 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and
  • m is zero or an integer in the range of 1 to 8.
  • only one of R50 or R51 may be a carbonyl, e.g., R50, R51 and the nitrogen together do not form an imide.
  • R50 and R51 each independently represent a hydrogen, an alkyl, an alkenyl, or -(CH2)m- R61.
  • alkylamine includes an amine group, as defined above, having a substituted or unsubstituted alkyl attached thereto, i.e., at least one of R50 and R51 is an alkyl group.
  • amino is art recognized as an amino- substituted carbonyl and includes a moiety that may be represented by the general formula:
  • acylamino is art-recognized and refers to a moiety that may be represented by the general formula: O
  • R50 wherein R50 is as defined above, and R54 represents a hydrogen, an alkyl, an alkenyl or - (CH 2 ) m -R61, where m and R61 are as defined above.
  • alkylthio refers to an alkyl group, as defined above, having a sulfur radical attached thereto.
  • the "alkylthio" moiety is represented by one of -S-alkyl, -S-alkenyl, -S-alkynyl, and -S-(CH2)m-R61, wherein m and R61 are defined above.
  • Representative alkylthio groups include methylthio, ethyl thio, and the like.
  • carbonyl is art recognized and includes such moieties as may be represented by the general formulas:
  • X50 is a bond or represents an oxygen or a sulfur
  • R55 and R56 represents a hydrogen, an alkyl, an alkenyl, -(CH 2 ) m -R61or a pharmaceutically acceptable salt
  • R56 represents a hydrogen, an alkyl, an alkenyl or -(CH 2 ) m -R61, where m and R61 are defined above.
  • X50 is an oxygen and R55 or R56 is not hydrogen
  • the formula represents an "ester”.
  • X50 is an oxygen
  • R55 is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R55 is a hydrogen, the formula represents a "carboxylic acid".
  • X50 is an oxygen, and R56 is hydrogen
  • the formula represents a "formate".
  • the oxygen atom of the above formula is replaced by sulfur
  • the formula represents a "thiolcarbonyl” group.
  • X50 is a sulfur and R55 or R56 is not hydrogen
  • the formula represents a "thiolester.”
  • X50 is a sulfur and R55 is hydrogen
  • the formula represents a "thiolcarboxylic acid.”
  • X50 is a sulfur and R56 is hydrogen
  • the formula represents a "thiolformate.”
  • X50 is a bond, and R55 is not hydrogen
  • the above formula represents a "ketone" group.
  • alkylthio refers to an alkyl group, as defined above, having a sulfur radical attached thereto.
  • the "alkylthio" moiety is represented by one of -S-alkyl, -S-alkenyl, -S-alkynyl, and -S-(CH2) m -R61, wherein m and R61 are defined above.
  • Representative alkylthio groups include methylthio, ethyl thio, and the like.
  • sulfonyl is art-recognized and refers to a moiety that may be represented by the general formula:
  • R58 may be one of the following: hydrogen, alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl or heteroaryl.
  • sulfoxido or "sulfinyl” is art-recognized and refers to a moiety that may be represented by the general formula:
  • compositions of the present invention may exist in particular geometric or stereoisomeric forms.
  • polymers of the present invention may also be optically active.
  • the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)- isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
  • Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
  • a particular enantiomer of compound of the present invention may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
  • the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically- active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
  • substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
  • the term "substituted" is also contemplated to include all permissible substituents of organic compounds.
  • the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
  • Illustrative substituents include, for example, those described herein above.
  • the permissible substituents may be one or more and the same or different for appropriate organic compounds.
  • the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
  • the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67 th Ed., 1986-87, inside cover.
  • the term "hydrocarbon” is contemplated to include all permissible compounds having at least one hydrogen and one carbon atom.
  • the permissible hydrocarbons include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic organic compounds that may be substituted or unsubstituted.
  • compositions of the present invention refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds, including, for example, those contained in compositions of the present invention.
  • the compounds of this disclosure may be formulated into therapeutic compositions as natural or salt forms.
  • Pharmaceutically acceptable non-toxic salts include the base addition salts (formed with free carboxyl or other anionic groups) which may be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino-ethanol, histidine, procaine, and the like.
  • Such salts may also be formed as acid addition salts with any free cationic groups and will generally be formed with inorganic acids such as, for example, hydrochloric, sulfuric, or phosphoric acids, or organic acids such as acetic, citric, p-toluenesulfonic, methanesulfonic acid, oxalic, tartaric, mandelic, and the like.
  • Salts contemplated herein include amine salts formed by the protonation of an amino group with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like.
  • Salts may also include amine salts formed by the protonation of an amino group with suitable organic acids, such as p-toluenesulfonic acid, acetic acid, and the like.
  • pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
  • materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
  • R 1 is selected from the group consisting of: -alkylene-R 5 -R 6 -R 2 , -R 6 -
  • R 2 is a heteroaryl optionally substituted by at one, two or three positions by halo, CN or alkyl;
  • R 3 independently for each occurrence, is selected from the group consisting of H, halo, CN, and NO 2 ;
  • R 4 is selected from the group consisting of thio, sulfonyl, or sulfinyl;
  • R 5 is selected from the group consisting of thio, sulfonyl, or sulfinyl;
  • Re is alkylene or a bond
  • any alkylene moiety may be a substituted alkylene moiety.
  • R 2 may be a bicyclic or monocyclic heteroaryl, e.g., benzothiazole, benzooxazole, quinoline, isoquinoline, or pyridine.
  • R 3 may be, in some embodiments, NO 2 , and one R 3 may be H.
  • R 4 is sulfonyl, e.g. -S(O) 2 -.
  • R 1 may be alkylene-S-heteroaryl, e.g. -CH 2 -CH 2 -S-heteraryl, where the heteroaryl may be optionally substituted at one, two or three positions by halo, alkyl, CN, or NO 2 ; for example, such heteroaryl may be substituted at only one position by cyano.
  • R 1 may be -alkylene-C(O)-phenyl, e.g. -CH 2 -C(O)-phenyl, or R 1 may be -alkylene-phenyl, e.g. -CH 2 -phenyl.
  • Such a phenyl moiety may be optionally substituted by one or two moieties selected from the group consisting of halo, alkyl, CN, or NO 2 , e.g. substituted by both a CN and NO 2 .
  • R 1 may be chosen from alkyl, alkenyl or alkynyl.
  • R 6 is a bond.
  • X is selected from the group of O, NR' and S; wherein R' is H or alkyl; for example, X may be S;
  • R 1 is selected from the group consisting of: -alkylene-R 5 -R 6 -R 12 , -R 6 -C(O)-R 12 , -
  • R 6 -R 12 alkyl, alkoxy, alkenyl, or alkynyl
  • R 4 is selected from the group consisting of thio, sulfonyl, or sulfinyl;
  • R 5 is selected from the group consisting of thio, sulfonyl, or sulfinyl;
  • R 6 is alkylene or a bond
  • R 12 is an aryl or heteroaryl optionally substituted by at one, two or three positions by halo, hydroxyl, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, amido, carbamoyl, sulphamoyl, ureido, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, or alkoxycarbonyl, and
  • R 3 independently for each occurrence, is selected from the group consisting of H, halo, cyano, hydroxyl, carboxy, alkyl, alkoxy, and nitro;
  • R 12 may be a bicyclic or monocyclic heteroaryl, e.g., benzothiazole, benzooxazole, quinoline, isoquinoline, or pyridine.
  • R 1 may be alkylene-S-heteroaryl, e.g. -CH 2 -CH 2 -S-heteroaryl, where the heteroaryl may be optionally substituted as defined for R 12 above.
  • R 3 is chosen from H or NO 2
  • R 1 is chosen from: t-butyl, ethyl, methyl,
  • a composition that includes one or more compounds of formula I or formula II, and a pharmaceutically acceptable excipient.
  • Compounds of formula I or formula II may, in some embodiments, inhibit H + , K + - ATPase, e.g., have proton pump inhibiting properties.
  • compositions disclosed herein may include a buffering agent that, in some embodiments, may protect the compounds against acid degradation.
  • buffering agents may include a weak or strong base, and/or may include one or more of sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium glucomate, aluminum hydroxide, aluminum hydroxide/sodium bicarbonate coprecipitate, a mixture of an amino acid and a buffer, a mixture of aluminum glycinate and a buffer, a mixture of an acid salt of an amino acid and a buffer, and a mixture of an alkali salt of an amino acid and a buffer.
  • Additional buffering agents include sodium citrate, sodium tartarate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogenphosphate, dipotassium hydrogenphosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium cholride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, and other calcium salts.
  • compositions disclosed herein may also include another chemotherapeutic agent, e.g. anthracyclines (e.g., doxorubicin and mitoxantrone), fluoropyrimidines (e.g., 5-FU, 5-fluorouracil), folic acid antagonists (e.g., methotrexate), podophylotoxins (e.g., etoposide), camptothecins, hydroxyureas, or platinum complexes (e.g., cisplatin).
  • anthracyclines e.g., doxorubicin and mitoxantrone
  • fluoropyrimidines e.g., 5-FU, 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • camptothecins hydroxyureas
  • platinum complexes e.g., cisp
  • chemotherapeutic agents may include a taxol, e.g. docetaxel or paclitaxel, etoposide, hormonal antieneoplastics, e.g. leuprolide or tamoxifen, IL-2, vinblastin, and vincristine.
  • compositions that include compounds of Formula I administered alone or in combination with other agents (e.g., chemotherapeutic agents or protein therapeutic agents described below).
  • agents e.g., chemotherapeutic agents or protein therapeutic agents described below.
  • compositions of the present invention may contain other therapeutic agents, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques known in the art of pharmaceutical formulation.
  • pharmaceutical additives for example, excipients, binders, preservatives, stabilizers, flavors, etc.
  • these pharmaceutical compositions may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences” (Mack Publishing Co, Easton Pa.). Suitable routes may, for example, include oral or transmucosal administration; as well as parenteral delivery, including intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration.
  • the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline.
  • penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • compositions disclosed herein can be administered, in some embodiments, with close association with the schedule of another chemo therapeutic.
  • administration can be prior to, simultaneously with or immediately following another therapeutic.
  • an article of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material
  • the packaging material comprises a label which indicates that the pharmaceutical composition can be used for treatment of cancer and/or gastrointestinal symptoms, alone or in conjunction with administration of chemotherapeutics
  • the pharmaceutical composition comprises at least one compound of formula I:
  • R 1 is selected from the group consisting of: -alkylene-R5-R6-R 2 , -R 6 -C(O)- phenyl, -R ⁇ -phenyl, alkyl, alkenyl or alkynyl, wherein the phenyl, independently for each occurrence, is optionally substituted by one or two moieties selected from the group consisting of halo, alkyl, CN, Or NO 2 ;
  • R 2 is a heteroaryl optionally substituted by at one, two or three positions by halo, CN or alkyl;
  • R 3 independently for each occurrence, is selected from the group consisting of H, halo, CN, and NO 2 ;
  • R 4 is selected from the group consisting of thio, sulfonyl, or sulfinyl;
  • R 5 is selected from the group consisting of thio, sulfonyl, or sulfinyl; and Re is alkylene or a bond; or pharmaceutically acceptable salts thereof.
  • Methods of treating cancer contemplated herein include methods of treating kidney cancer, ovarian cancer, leukemia, lung cancer, bladder cancer, breast cancer, liver cancer, thyroid cancer, lymphoma, Hodgkin's lymphoma, melanoma, myeloma, brain cancer, colon cancer, prostate cancer, bone cancer, renal cancer and cervical cancer.
  • Exemplary methods include methods of treating kidney cancer, small-cell lung cancer, non-small cell lung cancer and glioblastoma.
  • Such methods of treating cancer may also include administering another chemotherapeutic agent, such as those described above.
  • contemplated methods include administering an effective amount of at least one compound represented by formula II or I, and another chemotherapeutic agent in the same dosage form, or in separate dosage forms (either substantially simultaneously or sequentially).
  • one compound or formulation may be administered by one route, whereas the other active ingredient,e.g. another chemotherapeutic, may be administered by a different routes.
  • all the compounds may be administered by the same route.
  • Also contemplated herein is a method of improving the therapeutic efficacy of a chemotherapeutic agent, comprising administering to a patient in need thereof a compound represented by formula I or II as shown above.
  • the disclosed compounds may have proton pump inhibitory properties, which may lower a tumor cell's resistance to cytotoxic agents.
  • methods of reducing side effects e.g. reducing the severity or incidence of side effects associated with the administration of certain chemotherapeutic agents, e.g. methods of reducing the incidence of oral and/or gastrointentinal damage, comprising administering to patient in need thereof (e.g. a patient currently also being administered certain chemotherapeutics) are contemplated
  • kits for inhibiting tumor growth comprising administering a compound of formula I or II to e.g. reduce the size of tumor.
  • the survival rate of a patient in need thereof of a compound of formula I or II is greater than about 15% as compard to a subject administered a placebo.
  • methods for inhibitor tumor cell growth by administering a compound disclosed herein. Exemplary tumor cells which may be inhibited by such administration include: IGROVl (ovarian), OVCAR 8 (ovarian), ES-2 (ovarian), CA0V3 (ovarian), 0VCAR5
  • HCT-15 colon
  • SF-539 brain
  • SF295 brain
  • ST486 lymphoma
  • U251 brain
  • UACC-62 melanoma
  • Benzothiazole compounds of Formulas I and/or II can be prepared using a 2-thiol compound 1.
  • 1 reacts with another starting material, 2, wherein Q is a halogen and R 1 and R 3 are as defined above.
  • the reaction may occur at room temperature in an organic solvent such as ethanol or DMF.
  • the disclosed compounds may also be prepared by an acid catalyzed reaction of compounds 1 with e.g. 2-amino-benzyl alcohols.
  • Sulfoxide and sulfonyl containing compounds may be prepared by oxidation of benzothiazoles.
  • oxidizing agents include, for example, peracis, such a m- chloroperoxybenzoic acid; perestes; peroxides, such as hydrogen peroxide; sodium mtaperiodiate; selenium dioxide; manganese dioxide, idosobenze; and the like.
  • peracis such as a m- chloroperoxybenzoic acid
  • perestes peroxides, such as hydrogen peroxide; sodium mtaperiodiate; selenium dioxide; manganese dioxide, idosobenze; and the like.
  • Oxidization may be terminated by adding dimethylsulfide.
  • the disclosed compounds can also be prepared with the aid of methods described in U.S. Patent No. 6,906,078, hereby incorporated by reference.
  • Example 2 -Inhibition of a kidney tumor cell line Adherent cells are plated approximately 16-24 hours before the day of the experiment in 180 ⁇ l growth media. On the day of the experiment, the plated adherent cells are analyzed and counted and suspension cells are plated in 180 ⁇ l growth media. The compounds and vehicle are prepared. The resulting solutions are added to the cells. The cells are incubated at 37 0 C, 5% CO 2 for 48 hours. The media is then aspirated. The plate containing the cell suspension is then spun at 1500 RPM for 10 minutes. The media is slowly removed using a multichannel pipettor. 200 ⁇ l of MTT is added to each well to a concentration of 0.863mg/ml MTT in the growth media.
  • the cells are incubated at 37 0 C, 5% CO 2 for 4 hours and then aspirated.
  • the plate containing the cell suspension is then spun at 1500 RPM for 10 minutes.
  • the media is slowly removed using a multichannel pipettor. lOO ⁇ l of DMSO is added to each well.
  • the cells are incubated at 37 0 C, 5% CO 2 for 5 minutes and the absorbance is obtained at 560 nm using a Dynex Opsys MR plate reader.
  • Table Ia and Table Ib indicate the % inhibition of the G401 rhabdoid(kidney) cell line using various compounds as disclosed herein. For several compounds, as noted below, the assay was performed multiple times and the result of each run is reported and associated with a particular compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne, en partie, des composés et des compositions comprenant un radical thiazole, qui peuvent être utiles, par exemple, pour traiter des cancers, par exemple un cancer du rein.
PCT/US2008/066867 2008-06-13 2008-06-13 Composés de thiazole, compositions et procédés utilisant ces derniers Ceased WO2009151456A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08770971A EP2307010A1 (fr) 2008-06-13 2008-06-13 Composés de thiazole, compositions et procédés utilisant ces derniers
JP2011513469A JP2011522887A (ja) 2008-06-13 2008-06-13 チアゾール化合物及び組成物並びにその使用方法
CA2727595A CA2727595A1 (fr) 2008-06-13 2008-06-13 Composes de thiazole, compositions et procedes utilisant ces derniers
CN2008801303663A CN102112129A (zh) 2008-06-13 2008-06-13 噻唑化合物、组合物及其使用方法
PCT/US2008/066867 WO2009151456A1 (fr) 2008-06-13 2008-06-13 Composés de thiazole, compositions et procédés utilisant ces derniers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/066867 WO2009151456A1 (fr) 2008-06-13 2008-06-13 Composés de thiazole, compositions et procédés utilisant ces derniers

Publications (1)

Publication Number Publication Date
WO2009151456A1 true WO2009151456A1 (fr) 2009-12-17

Family

ID=40303565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/066867 Ceased WO2009151456A1 (fr) 2008-06-13 2008-06-13 Composés de thiazole, compositions et procédés utilisant ces derniers

Country Status (5)

Country Link
EP (1) EP2307010A1 (fr)
JP (1) JP2011522887A (fr)
CN (1) CN102112129A (fr)
CA (1) CA2727595A1 (fr)
WO (1) WO2009151456A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115124485B (zh) * 2021-03-26 2023-12-15 中国医学科学院药物研究所 一类含亚砜的苯并恶唑衍生物及其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2135543A1 (de) * 1971-07-16 1973-01-25 Boehringer Mannheim Gmbh Benzthiazolderivate enthaltende arzneimittel
EP0067685A1 (fr) * 1981-06-15 1982-12-22 American Home Products Corporation Acides alpha-phényl-2-(aza)benzothiazolylthioglycoliques et leurs dérivés
US5919807A (en) * 1995-05-12 1999-07-06 Dr. Karl Thomae Gmbh Benzothiazoles and benzoxazoles, drugs containing them, their use and methods of preparing them
WO2003106430A1 (fr) * 2002-06-14 2003-12-24 Pfizer Inc. Inhibiteurs benzimidazole de la poly(adp-ribosyl) polymerase
WO2005083107A2 (fr) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition de la superoxyde-dismutase par le tetrathiomolybdate : identification de nouveaux agents anti-angiogeniques et de nouveaux agents antitumoraux
US20070203236A1 (en) * 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2007103273A2 (fr) * 2006-03-03 2007-09-13 Trustees Of Boston University Inhibiteurs de la thioredoxine et de la thioredoxine reductase

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2135543A1 (de) * 1971-07-16 1973-01-25 Boehringer Mannheim Gmbh Benzthiazolderivate enthaltende arzneimittel
EP0067685A1 (fr) * 1981-06-15 1982-12-22 American Home Products Corporation Acides alpha-phényl-2-(aza)benzothiazolylthioglycoliques et leurs dérivés
US5919807A (en) * 1995-05-12 1999-07-06 Dr. Karl Thomae Gmbh Benzothiazoles and benzoxazoles, drugs containing them, their use and methods of preparing them
WO2003106430A1 (fr) * 2002-06-14 2003-12-24 Pfizer Inc. Inhibiteurs benzimidazole de la poly(adp-ribosyl) polymerase
WO2005083107A2 (fr) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition de la superoxyde-dismutase par le tetrathiomolybdate : identification de nouveaux agents anti-angiogeniques et de nouveaux agents antitumoraux
US20070203236A1 (en) * 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2007103273A2 (fr) * 2006-03-03 2007-09-13 Trustees Of Boston University Inhibiteurs de la thioredoxine et de la thioredoxine reductase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOCI, JAN ET AL: "Heterocyclic benzazole derivatives with antimycobacterial in vitro activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 12(22), 3275-3278 CODEN: BMCLE8; ISSN: 0960-894X, 2002, XP002513882 *
ZHANG LIN ET AL: "7 '-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 17, August 2006 (2006-08-01), pages 5352 - 5362, XP002513881, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
JP2011522887A (ja) 2011-08-04
EP2307010A1 (fr) 2011-04-13
CN102112129A (zh) 2011-06-29
CA2727595A1 (fr) 2009-12-17

Similar Documents

Publication Publication Date Title
KR102635986B1 (ko) 카르복시 치환된 (헤테로) 방향족 고리 유도체 및 이의 제조 방법과 용도
CA2804034C (fr) Promedicaments de composes heteroaromatiques
CN119868365A (zh) 治疗特发性肺纤维化的方法
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
WO2019217509A1 (fr) Compositions et méthodes pour le traitement du cancer
JPH04502462A (ja) 治療上活性な置換されたベンズイミダゾールおよびその製法
WO2014116962A1 (fr) Inhibiteurs sélectifs de l'histone désacétylase 8
CA2149691A1 (fr) Agent pharmaceutique utilise a des fins therapeutiques et prophylactiques pour traiter les maladies causees par l'hyperplasie des cellules des muscles lisses
WO2008124823A1 (fr) Méthode de traitement du mélanome
EP4244222B1 (fr) Succinate et sa forme cristalline utilisés en tant qu'agents thérapeutiques
EP2307010A1 (fr) Composés de thiazole, compositions et procédés utilisant ces derniers
HK1199250A1 (en) Biaryl heterocycle substituted oxazolidinon antibacterial drug
US8173688B2 (en) Thiazole compounds, and compositions and methods using same
EP3641756B1 (fr) Composés tricycliques utilisés comme inhibiteurs du cyp1
EP2902028A1 (fr) Composition médicamenteuse pour le traitement de tumeurs et application de celle-ci
EP4009973B1 (fr) Compositions pharmaceutiques de (6as)-6-méthyl -5,6,6a,7-tétrahydro-4 h-dibenzo[de,g]quinoléine-10,11-diol
AU2018404329A1 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
JPH0640990A (ja) 新規化合物
JP2005507869A (ja) 特殊構造を持つ新規抗癌化合物の一群
JP5955531B2 (ja) 抗癌剤
JP2024529073A (ja) 脳がんを治療する方法
WO2024089272A1 (fr) Nouveaux inhibiteurs de la phosphatidylinositol 3-kinase
CN118638110A (zh) 一种用于治疗恶性黑色素瘤的药物
JP2014015441A (ja) 抗癌剤
HK40029607A (en) Tricyclic compounds as cyp1 inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880130366.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08770971

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2727595

Country of ref document: CA

Ref document number: 2011513469

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008770971

Country of ref document: EP